War on morphine for ACS purposely obscures the data
from Emergency Medicine News
A number of publications recently maligned the use of morphine for treating acute coronary syndrome (ACS). The hypothesis is that morphine slows the absorption of the oral P2Y12 inhibitors such as ticagrelor, delaying the dual-platelet inhibition desired by cardiologists. The most recent data supporting this hypothesis was in a study appropriately entitled the IMPRESSION trial. Its results propagated a concept that appears valid on the surface but may not accurately represent the underlying reality.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063